Full history for every metric is available with a Kvantra account
Key financial summary
Financials in GBP| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | £bn | 34.1 | 24.7 | 29.3 | 30.3 | 31.4 | 32.7 | 33.2 | 33.8 |
| Operating profit | £bn | 7.17 | 8.01 | ||||||
| Net profit | £bn | 5.7 | 4.4 | 15.0 | 4.9 | 2.6 | 5.7 | 4.8 | 7.2 |
| EPS reported | £ | 1.39 | 1.19 | ||||||
| Operating cashflow per share | £ | 1.80 | 1.99 | ||||||
| Capex per share | £ | 0.33 | 0.55 | ||||||
| FCF per share | £ | 1.47 | 1.43 | ||||||
| Free cash flow | £bn | 5.96 | 5.76 | ||||||
| Net debt | £bn | 13.7 | 15.1 | ||||||
| Book value equity | £bn | 16.4 | 17.6 | ||||||
| Book value per share | £ | 3.98 | 4.34 | ||||||
| Number of shares | m | 4,117 | 4,062 | ||||||
| DPS (TTM paid) | £ | 0.64 | 0.68 |
Financial summary
Financials in GBP| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 13.13 | 14.88 | ||||||
| P/B LTM | x | 4.51 | 3.99 | ||||||
| P/S LTM | x | 2.26 | 2.12 | ||||||
| P/FCF LTM | x | 12.41 | 12.25 | ||||||
| EV/EBITDA LTM | x | 7.45 | 8.01 | ||||||
| EV/Sales LTM | x | 2.71 | 2.58 | ||||||
| Earnings Yield LTM | % | 7.62% | 6.72% | ||||||
| FCF Yield | % | 8.06% | 8.17% | ||||||
| Quality | |||||||||
| ROE | % | 34.90% | 28.35% | ||||||
| ROIC | % | 14.25% | 16.04% | ||||||
| Operating margin | % | 21.95% | 24.12% | ||||||
| Gross margin | % | 72.54% | 73.29% | ||||||
| FCF/Sales | % | 18.23% | 17.34% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +123.58% | +43.37% | ||||||
| Sales Growth YoY | % | +4.11% | +4.97% | ||||||
| Net Income Growth YoY | % | +121.98% | +40.84% | ||||||
| FCF Growth | % | +66.71% | +10.63% | ||||||
| Operating Profit Growth | % | +26.62% | +47.03% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 3.47% | 3.84% | ||||||
| Dividend Growth | % | +4.92% | +7.94% | ||||||
| Payout Ratio | % | 44.80% | 54.90% | ||||||
| FCF/Debt | x | 0.34 | 0.32 | ||||||
| Net Debt/EBITDA | x | 1.23 | 1.42 | ||||||
| EBIT/Net interest | x | 10.23 | 11.37 | ||||||
| Net debt/market cap | % | 18.58% | 21.47% | ||||||
| Net debt/Equity | x | 0.84 | 0.86 | ||||||
| Gross debt/equity | x | 1.08 | 1.03 | ||||||
ETFs that hold GSK
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| Vanguard FTSE 100 UCITS ETF (GBP) Distributing | VUKE.L | 9 | 2.87% |
| Amundi UK Equity All Cap UCITS ETF Dist | LCUK.L | 9 | 2.73% |
| Hartford Multifactor Developed Markets (ex-US) ETF | RODM | 6 | 0.89% |
| VanEck Pharmaceutical ETF | PPH | 9 | 4.34% |
| State Street SPDR FTSE UK All Share UCITS ETF (Acc) | FTAL.L | 9 | 2.43% |
| Franklin FTSE United Kingdom ETF | FLGB | 9 | 2.88% |
| GMO International Value ETF | GMOI | 9 | 2.32% |
| State Street SPDR MSCI Europe Health Care UCITS ETF | HLTH.L | 5 | 5.45% |
| BetaShares - FTSE 100 ETF | F100.AX | 9 | 2.78% |
| Neuberger Berman ETF Trust - International Core Equity ETF | NBIE | 8 | 1.39% |
Funds with GSK among their ten largest holdings, largest fund first.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
GSK plc is a global pharmaceutical and healthcare company, deeply involved in the research, development, production, and commercialization of a diverse range of medicinal and wellness products. Its operations span the United Kingdom, the United States, and numerous other international markets. The company structures its operations across four primary divisions: Pharmaceuticals, Pharmaceutical R&D, Vaccines, and Consumer Healthcare. Within its Pharmaceuticals segment, GSK provides treatments addressing a wide array of therapeutic areas. These include respiratory conditions, HIV, immuno-inflammatory diseases, oncology, viral infections, central nervous system disorders, cardiovascular and urogenital health, metabolic imbalances, bacterial infections, and dermatological issues. The Consumer Healthcare division offers products across categories such as wellness, oral hygiene, nutritional supplements, and skin health. These consumer offerings come in a variety of formats, including oral dosage forms (e.g., tablets, syrups, lozenges, gummies, soft chews, effervescents), topical applications (e.g., gels, creams, patches, lip balms), nasal sprays, and a comprehensive range of oral hygiene products (e.g., toothpastes, mouthwashes, denture care items), alongside other specialized formulations like infant drops and wipes. GSK actively engages in various collaborative ventures. Its collaboration agreements include partnerships with 23andMe, Lyell Immunopharma, Inc., Novartis, Sanofi SA, Surface Oncology, Progentec Diagnostics, Inc., Alector, Inc., and CureVac AG. Additionally, the company maintains strategic alliances with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. Originally established in 1715, the company operated under the name GlaxoSmithKline plc until its rebranding to GSK plc in May 2022. Its corporate headquarters are situated in Brentford, United Kingdom.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| Vanguard FTSE 100 UCITS ETF (GBP) Distributing | VUKE.L | 9 | 2.87% |
| Amundi UK Equity All Cap UCITS ETF Dist | LCUK.L | 9 | 2.73% |
| Hartford Multifactor Developed Markets (ex-US) ETF | RODM | 6 | 0.89% |
| VanEck Pharmaceutical ETF | PPH | 9 | 4.34% |
| State Street SPDR FTSE UK All Share UCITS ETF (Acc) | FTAL.L | 9 | 2.43% |
| Franklin FTSE United Kingdom ETF | FLGB | 9 | 2.88% |
| GMO International Value ETF | GMOI | 9 | 2.32% |
| State Street SPDR MSCI Europe Health Care UCITS ETF | HLTH.L | 5 | 5.45% |
| BetaShares - FTSE 100 ETF | F100.AX | 9 | 2.78% |
| Neuberger Berman ETF Trust - International Core Equity ETF | NBIE | 8 | 1.39% |
Funds with GSK among their ten largest holdings, largest fund first.
Based on consensus from external analysts. Not Kvantra's opinion.
GSK plc is a global pharmaceutical and healthcare company, deeply involved in the research, development, production, and commercialization of a diverse range of medicinal and wellness products. Its operations span the United Kingdom, the United States, and numerous other international markets. The company structures its operations across four primary divisions: Pharmaceuticals, Pharmaceutical R&D, Vaccines, and Consumer Healthcare. Within its Pharmaceuticals segment, GSK provides treatments addressing a wide array of therapeutic areas. These include respiratory conditions, HIV, immuno-inflammatory diseases, oncology, viral infections, central nervous system disorders, cardiovascular and urogenital health, metabolic imbalances, bacterial infections, and dermatological issues. The Consumer Healthcare division offers products across categories such as wellness, oral hygiene, nutritional supplements, and skin health. These consumer offerings come in a variety of formats, including oral dosage forms (e.g., tablets, syrups, lozenges, gummies, soft chews, effervescents), topical applications (e.g., gels, creams, patches, lip balms), nasal sprays, and a comprehensive range of oral hygiene products (e.g., toothpastes, mouthwashes, denture care items), alongside other specialized formulations like infant drops and wipes. GSK actively engages in various collaborative ventures. Its collaboration agreements include partnerships with 23andMe, Lyell Immunopharma, Inc., Novartis, Sanofi SA, Surface Oncology, Progentec Diagnostics, Inc., Alector, Inc., and CureVac AG. Additionally, the company maintains strategic alliances with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. Originally established in 1715, the company operated under the name GlaxoSmithKline plc until its rebranding to GSK plc in May 2022. Its corporate headquarters are situated in Brentford, United Kingdom.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free